Latest in AIMS Psilocybin Right-To-Try Effort

Latest in AIMS Psilocybin Right-To-Try EffortWe have taken an additional step recently in our effort to secure psilocybin therapeutic use for two of our cancer patients under State and Federal Right to Try (RTT) laws. On Monday 3/8/21, on behalf of AIMS Institute and Dr. Aggarwal, lawyers filed a petition for review in U.S. Ninth Circuit Court of Appeals of the DEA’s written decision last month to deny our request for RTT access to psilocybin from a duly licensed producer.

Below is the press release that went out and links to some news stories that have appeared.

We are looking for leading organizations committed to protecting the rights of seriously ill patients to have immediate access to safe use of psychedelic-assisted therapy to file ‘friend of the court’ amicus briefs in the case. Please get in touch if your organization or one you know of is interested in lending their voice of support to help our patients receive therapeutic access to the eligible investigational drug psilocybin under right to try. We have a great opportunity here to help advance this very needed therapeutic modality in contemporary hospice and palliative care. Patients treated by palliative care and mental health specialists in Canada have already been able to avail fungal psilocybin-assisted therapy legally under Canadian government exemptions for the past 7 months, and it has been very beneficial in palliation of existential and other distress by all reports.

Press Release: NATION’S FIRST LEGAL CHALLENGE TO ALLOW PSILOCYBIN THERAPY IN END-OF-LIFE CARE UNDER “RIGHT-TO-TRY” LAWS MOVES FORWARD
https://goteamtbg.com/dying-patients-need-access-to-psilocybin-for-anxiety-and-depression-relief/

Oregon Public Broadcasting: Physicians ask DEA to rethink ban on psilocybin
https://www.opb.org/article/2021/03/09/physicians-ask-dea-to-rethink-ban-on-psilocybin/

Marijuana Moment: DEA Sued By Doctor Who Wants Permission To Give Psilocybin Mushrooms To Patients
https://www.marijuanamoment.net/dea-sued-by-therapists-who-want-permission-to-give-psilocybin-mushrooms-to-patients/

Clinician, Patients Take the Fight for Psilocybin To Court
https://www.psychiatrictimes.com/view/clinician-patients-take-fight-psilocybin-to-court

Why Dying Patients Are Suing for Access to Magic Mushrooms
https://today.westlaw.com/Document/Icf70e0e081e411eb835ee9025e2233da/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0

Seattle Doctor, Lawyer Speak Out on Landmark DEA Psilocybin Lawsuit
truffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

Seattle Doctor, Lawyer Speak Out on Landmark DEA Psilocybin Lawsuit
truffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

Suing the DEA for Access to Psilocybin
https://www.mushroomrevival.com/blogs/podcast/suing-the-dea-for-access-to-psilocybin?fbclid=IwAR1QLWYCMjISeWOdoHQVqlb1PaI1iA8NvsSgh7rut71VqZDQpAjU089fUBstruffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

 

Latest Blog Posts

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

Healthcare Disparities in African American Communities African Americans continue to face significant disparities in healthcare. From higher mortality rates for chronic conditions like cancer and heart disease to underdiagnosis of autoimmune disorders, these inequities stem from systemic racism, implicit bias, and a lack of cultural sensitivity among providers. Studies show that Black patients are less likely to receive adequate pain management and more likely to feel unheard or dismissed during medical visits. These disparities erode trust in the healthcare system and lead to poorer outcomes and avoidable suffering. For many, navigating the system can feel isolating and disempowering, leaving them ...

Read More
At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

A recent paper in the Frontiers in Medicine states that An underutilized intervention for long  COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue ...

Read More
Unusual Suspects

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy SEAL — including missions with SEAL Team Six, the nation’s preeminent counterterrorism unit — before being medically retired in 2013. For years, he struggled to find effective treatments for his traumatic brain injuries, depression, and post-traumatic stress disorder. Capone tried antidepressants, talk therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and he visited several brain clinics. Nothing worked. When Capone’s life began falling apart, he considered suicide. His wife was just as ...

Read More
Call Us Text Us
Skip to content